BioMarin Pharmaceutical
San Rafael
About BioMarin Pharmaceutical
BioMarin Pharmaceutical develops and delivers therapies for rare genetic and metabolic conditions. The company applies scientific research to understand the underlying causes of diseases and creates medicines using multiple treatment approaches.Its portfolio includes therapies for achondroplasia, severe hemophilia A, and various lysosomal storage disorders. BioMarin conducts clinical and preclinical research to expand its pipeline of investigational treatments. The company emphasizes collaboration with patient communities to inform therapy development and focuses on translating genetic discoveries into potential new medicines. Its operations encompass research, development, and manufacturing of specialized therapies for complex conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $1M – $10M
- Total funding: $4.2B
- Funding stage: IPO
- Last round: Post-IPO Debt (Jan 2026)
- Ticker: nasdaq:BMRN
- Website: biomarin.com
- Phone: +1 415-506-6700
Industries & Categories
Biotechnology, Developer Platform, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/biomarin-pharmaceutical-61734 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.